LifeMD, Inc. has added Eli Lilly’s first once‑daily oral GLP‑1 therapy, Foundayo (orforglipron), to its weight‑management lineup. The drug received FDA approval on April 1 2026 and is the second oral GLP‑1 option after Wegovy’s pill, which was approved in December 2025.
Foundayo is priced at $149 per month for the initial dosage under self‑pay. Commercial‑insurance patients can access the therapy through LillyDirect at a discounted rate of $25 per month using a Lilly savings card. Medicare coverage is expected to begin in July 2026, expanding access for seniors who rely on the program.
The launch is part of LifeMD’s strategy to broaden its telehealth‑based weight‑management platform. By integrating with LillyDirect, the company can ship prescriptions directly to patients, streamlining the patient experience. "By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point. LifeMD remains dedicated to expanding access to high‑quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment," said LifeMD CEO Justin Schreiber.
Eli Lilly’s Group Vice President of U.S. Cardiometabolic Health, Laura Steele, noted, "The availability of Foundayo reflects Lilly's continued commitment to advancing clinical innovations for patients. We're committed to expanding access to treatment options through channels that meet patients where they are in their journey."
LifeMD’s Q4 2025 results provide context for the launch. Revenue rose 4% year‑over‑year to $46.9 million, while full‑year 2025 revenue increased 25% to $194.1 million. The company reported a GAAP net loss of $1.9 million in Q4 2025, driven by aggressive expansion costs. Management highlighted near‑term discretionary investments in GLP‑1 marketing and platform expansion that are expected to depress Q1 2026 EBITDA but will drive higher revenue and adjusted EBITDA run‑rates by late 2026.
Guidance for 2026 reflects confidence in the expanded portfolio. LifeMD forecasts full‑year revenue of $220–$230 million and adjusted EBITDA of $12–$17 million. The company projects Q4 2026 annualized run‑rates of over $250 million in revenue and more than $25 million in adjusted EBITDA, signaling a return to profitability in the second half of the year.
The Foundayo launch builds on LifeMD’s existing partnership with Novo Nordisk for Wegovy, positioning the company as a provider of both branded GLP‑1 therapies. The addition of a second oral option strengthens its competitive stance in a rapidly expanding market for weight‑management treatments.
revised_sentiment_rating":5}]}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.